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INTRODUCTION
In modern anesthesia practice, most general surger-
ies are carried out with ease using neuromuscular 
blocking agents. A neuromuscular blocker agent 
should ideally have high potency, rapid onset, and 
short clinical duration. It should evade any hemo-
dynamic changes due to histamine release, ganglion 
block, and anti-muscarinic actions.1,2 
Cisatracurium is a recent benzylisoquinoline 
introduced in 1989 by Hill and Turner. It lacks 
histamine-releasing properties and undergoes 
Hoffmann elimination.3 Rocuronium is a steroidal 
non-depolarising muscle relaxant (NDMR). Its 
potency is 1/6 of vecuronium. Its principal route of 
elimination is by the liver and, to a little extent, the 
kidneys.4 
This study was aimed to see if twice the dose of 
ED95 of cisatracurium and rocuronium differ in 
regards to their onset of action, clinical duration, 
recovery index, intubating conditions, efficacy, and 
safety in elective surgery.
PATIENTS AND METHODS 
This was a hospital-based, prospective, random-
ized, interventional, and double-blind study. After 
achieving permission from our institutional review 
board and ethical committee, we obtained writ-
ten informed consent from 60 subjects. Inclusion 
criteria were American Society of Anesthesiologists 
(ASA) physical status I & II, nonobese patients, aged 
20-50 years, Mallampati class I & II upon pre-anes-
thesia evaluation, and undergoing elective surgery 
of 45 minutes duration under general anesthesia. 
The minimal sample size was calculated based 
on the results of a previous study.5 Patients were 
randomized by computer-generated sequence, and 
allotment was done by sealed envelope method. 
Patients with major hepatic, renal, cardiovascu-
lar, pulmonary and neuromuscular disease, on 
any preoperative medication interfering with 
neuromuscular transmission, and patients requir-
ing more than three attempts at intubation were 
excluded from the study.
Standard ASA monitoring was applied in the 
operating theatre: electrocardiography, pulse oxim-
etry (SpO2), heart rate, blood pressure (NIBP), body 
temperature, and end-tidal carbon dioxide concen-
tration (EtCO2). Acceleromyography method of the 
evoked response by STIMPOD Xavant NMS450 
was used for neuromuscular monitoring. It includes 
features like accurate and real-time neuromuscular 
transmission (NMT) monitoring, nerve mapping 
and location, and reusable 3D acceleromyography 
(AMG) sensor. The electrodes were applied at the 
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ABSTRACT
Background: Most surgeries are carried out with ease using 
neuromuscular blocking agents. This study was aimed to compare the 
intubating dose of cisatracurium and rocuronium regarding the onset 
of action, clinical duration, recovery index, intubating conditions, 
efficacy, and safety in elective surgery. 
Method: 60 adult patients of American Society Anesthesiology (ASA) 
grade I & II, underwent elective laparoscopic surgery were randomized 
to receive either cisatracurium 0.1 mg/kg (Group C) or rocuronium 
0.6 mg/kg (Group R). Neuromuscular monitoring was done using 
STIMPOD Xavant NMS450. Relaxogram interpretation was carried out 
for the onset of action, clinical duration, and recovery index.
Results: Cisatracurium had significant longer onset (233.33±62.31 
vs. 86.66±28.62 seconds, p <0.001) and significant longer 
clinical duration (40±3.56 vs. 27.46±2.14 minutes, p <0.001) 
than rocuronium. Recovery index was significantly longer in the 
cisatracurium group (12.23±1.54 vs. 8.30±1.80 minutes, p <0.001). 
Clinically acceptable intubating conditions were achieved in 180 
seconds (C group) compared to 60 seconds in the R group. No untoward 
or adverse response and complications were distinguished in either 
group. 
Conclusion: Cisatracurium 0.1 mg/kg exhibited a slower onset of 
action than rocuronium 0.6 mg/kg and provided excellent intubating 
conditions in the majority of patients after 180 seconds. The clinical 
duration and recovery index were significantly longer in cisatracurium 
compared to rocuronium. Both are potent and safe agents with 
excellent cardiovascular stability.
Keywords: neuromuscular relaxants, cisatracurium, rocuronium, monitoring, train of four.
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volar side of the wrist. The distal electrode was 
placed 1 cm proximal to the proximal flexion crease 
of the wrist, and the other electrode was placed 
4 cm proximal to the distal electrode.
All patients were given intravenous (IV) raniti-
dine 50 mg, metoclopramide 10 mg, glycopyrrolate 
(0.005 mg/kg), and midazolam (0.02 mg/kg) as 
premedication. We induced anesthesia by 2 mcg/kg 
fentanyl and 2 mg/kg propofol. Before neuromus-
cular drug administration, the accelerometer was 
calibrated using 0.2 ms supramaximal square wave 
impulse at 2 Hz. The ulnar nerve was stimulated at 
the wrist with the supramaximal stimulus of 0.2 ms 
duration, in a TOF (train of four) mode at 2 Hz 
every 20 seconds. 
Patients were randomized using a sealed enve-
lope technique to receive either cisatracurium 
0.1 mg/kg (Group C) or rocuronium 0.6 mg/kg 
(Group R), both diluted to 10 mL. The first intu-
bation attempt was made by the anesthesiologist 
when the TOF ratio was 0/4, indicating the onset of 
action. Intubating conditions were assessed using 
a four-point scale: (1) Excellent – easy passage of 
the tracheal tube without coughing, vocal cords 
relaxed; (2) Good – light coughing, vocal cords 
relaxed; (3) Poor – passage of tracheal tube with 
moderate coughing or bucking , some movement 
of the vocal cords; and (4) impossible.6 
Anesthesia was maintained with 60% nitrous 
oxide (N2O) in oxygen (O2) and isoflurane to 
total MAC of 1.5. Mechanical ventilation was 
adjusted to maintain EtCO2 between 35-40mmHg. 
Hemodynamics parameters were recorded every 
five minutes throughout the study. After 15 minutes 
of an intubating dose of muscle relaxant in both the 
groups, TOF stimulation repeated every 3 minutes 
until 25% of twitch height achieved, which indi-
cated the clinical duration. 
After the surgery, we used 50 mcg/kg neostig-
mine and 0.4 mg glycopyrrolate to antagonize the 
neuromuscular blockade. Then, TOF stimulation 
was repeated every 20 seconds, and recovery index 
was recorded, which defined as achieving 75% of 
twitch height. We extubated the patient when the 
patients regained consciousness with adequate 
muscle power.
The following parameters were logged in both 
groups: onset time, clinical duration, and recovery 
index. The onset time was defined as the duration 
from neuromuscular blocker (NMB) administra-
tion to TOF ratio 0/4. The clinical duration was 
defined as the duration from NMB injection to 25% 
recovery of twitch height (recorded in minutes). 
And the recovery index was defined as the dura-
tion from 25% to 75% recovery of twitch height 
(recorded in minutes).
We used Statistical Packages for Social Sciences 
(SPSS) version 21 for the statistical analysis. 
Chi-square test was utilized for comparison of cate-
gorical data. Quantitative data were presented as 
mean and standard deviation and were compared 
by student t-test. A p value of <0.05 was considered 
statistically significant. 
RESULTS
Demographics variables and the results of the study 
are presented in Table 1. There was no significant 
difference regarding the distribution of age between 
the two groups. Transient diastolic and mean blood 
pressure after induction and transient tachycar-
dia after intubation were recorded, as shown in 
Figures 1 and 2. The excellent intubating conditions 
in this study were achieved in 22 patients in group 
C and 23 patients in group R. The good intubating 
conditions were seen in 8 patients in group C and 7 
patients in group R.
The mean onset of action in group C 
was 233.33±62.31 seconds compared to 
86.66±28.62 seconds in group B (p <0.001). The mean 
duration of cisatracurium was 40±3.56 minutes 
compared to rocuronium’s 27.46±2.14  minutes 
(p <0.001). The mean recovery index in group 
C was 12.23±1.54 minutes, and in group R was 
8.30±1.80  minutes (p <0.001). No untoward or 
adverse reaction and complications were noted.
DISCUSSION
In our study, both groups were comparable in terms 
of age, weight, and Mallampati class, ensuring that 
there was no confounding bias (Table 1). As shown 
in figures 1&2, the hemodynamic variables were 
comparable in both the groups. There was a tran-
sient fall in systolic, diastolic, and mean arterial 
blood pressure after induction in both the groups, 
which was statistically insignificant.
The mean onset of action of cisatracurium 
0.1  mg/kg was 233.33±81.71 seconds, and with 
rocuronium 0.6 mg/kg was 86.66±28.41 seconds 
(p <0.001), which showed that the onset of action 
was significantly longer with cisatracurium group 
as compared to the rocuronium group. Other 
studies reported that the faster onset of action of 
rocuronium could be attributed to the fact that low 
potency neuromuscular blockers like rocuronium 
have more molecules to diffuse from the central 
compartment into the effect compartment, where 
they act promptly.6-8 Weaker binding of low potency 
drugs to receptors prevent buffered diffusion, and 
more molecules occupy receptors causing rapid 
onset. Potent drugs like cisatracurium undergo 
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buffered diffusion causing repetitive binding and 
unbinding to receptors, so onset is prolonged. 
Our study is in agreement to results documented 
by Carroll et al.9 who observed median onset time 
as 3.4 minutes for cisatracurium and 1 minute for 
rocuronium. Kim et  al.10 also reported median 
onset time with cisatracurium group as 3.9 minutes, 
which is similar to our study. However, few authors 
have reported a slight difference in onset time with 
cisatracurium and rocuronium as compared to our 
study, which could be attributed to methodologi-
cal differences in recording the onset time. In our 
study, the onset of action was recorded when the 
TOF ratio was 0/4.5
The mean duration of action in our study 
was 40±3.56 minutes for cisatracurium and 
27.46±2.14 minutes for rocuronium. It is in agree-
ment with Carroll et al.9 who observed the median 
duration of action for cisatracurium at 0.1mg/
kg was 41 minutes and rocuronium at 0.6mg/kg 
was 33 minutes. Hofmockel et  al.11 studied endo-
tracheal intubation with 0.6 mg/kg rocuronium 
using mechanomyographic and electromyographic 
neuromuscular monitoring and reported the dura-
tion of action as 28.4±8 minutes. Puhringer et al.12 
observed the duration of action for rocuronium 
was 25.3±5 minutes, which is similar to our study. 
The mean recovery index in our study for cisa-
tracurium (12.23±1.54 minutes) was significantly 
longer than rocuronium (8.30±1.80 minutes). 
Lepage et al.13 reported recovery index for cisatra-
curium was 15 minutes, while Puhringer et  al.12 
observed recovery index with rocuronium as 
7.8±2.1 minutes, which is similar to our study. 
Another study recorded that recovery index after a 
single dose of rocuronium was 12±5 minutes with 
isoflurane and 26±11.7 minutes with sevoflurane.14 
The reported recovery index with isoflurane is 
comparable to our study. The prolonged recovery 
index with sevoflurane is probably due to faster and 
more complete equilibrium among the end-tidal, 
blood, and muscle concentrations of sevoflurane 
because of its smaller muscle-gas partition coeffi-
cient resulting in slow recovery.
The excellent intubating conditions in our study 
were seen in 22 patients in group A and 23 patients 
in group B. The good intubating conditions were 
seen in 8 patients in group A and 7 patients in 
group B. We attempted intubation in both groups 
for the first time only when we found TOF to be 
0/4 at adductor pollicis. Since vocal cords and other 
laryngeal muscles are affected more rapidly than 
the adductor pollicis muscle, we obtained excellent 
and good intubating conditions in all our patients 
in both groups. It is in contrast to previous studies 
that attempted intubation at 60 seconds irrespective 
of the twitch height.6,12 
T1: after induction and before injection of NMB 
T2: after injection of NMB and before endotracheal intubation
T3: just after intubation
Figure 1  Comparison of the mean arterial pressure (MAP)
Figure 2 Comparison of the pulse rate
T1: after induction and before injection of NMB 
T2: after injection of NMB and before endotracheal intubation
T3: just after intubation
Table 1  Study variables and observation results
Variables Group C Group R p
Age, mean±SD 39.50±8.06 35.90±7.29
Body weight (kg), mean±SD 59.07±6.08 61.60±9.16
Mallampati class, mean±SD 1.27±0.45 1.27±0.45
Intubating condition at TOF 0/4: 
Excellent, n(%) 22 (73.3) 23 (76.7)
Good, n(%) 8 (26.7) 7 (23.3)
Poor, n(%) 0 0
Impossible, n(%) 0 0
Onset of action (seconds), mean±SD 233.33±62.31 86.66±28.62 <0.001a
Clinical duration (minutes), mean±SD 40.00±3.56 27.46±2.14 <0.001a
Recovery index (minutes), mean±SD 12.23±1.54 8.30±1.80 <0.001a
C: cisatracurium; R: rocuronium; SD: standard deviation; TOF: train of four; aChi-square
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The intubating conditions after cisatracurium in 
our study were only acceptable after 180 seconds, 
and this is similar to a previous study.5 Chetty 
et al.15 found that the percentage of good or excel-
lent intubating conditions at 60 seconds was 80% 
for rocuronium but only 12.5% for atracurium. 
Inconsistent with our results, Zhou et al.8 reported 
84% clinically accepted intubating conditions with 
rocuronium after 60 seconds. 
No adverse effects in terms of cardiovascular 
instability, bronchospasm, or cutaneous flushing 
due to histamine release were observed in any 
patient in either group in our study. Various studies 
have also reported a safe clinical profile with no 
adverse events with the use of cisatracurium and 
rocuronium.5,13,16
CONCLUSION 
Cisatracurium 0.1mg/kg exhibited a slower onset 
of action compared to rocuronium 0.6 mg/kg but 
provided acceptable intubating conditions in the 
majority of patients after 180 seconds. The clini-
cal duration and recovery index were significantly 
longer in cisatracurium compared to rocuronium. 
Both agents are potent and safe with excellent 
cardiovascular stability. These data suggest that 
cisatracurium is a useful addition to the arma-
mentarium of currently available non-depolarizing 
neuromuscular blocking drugs for patients under-
going long duration surgical procedures.
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